藥物研究評論：2023 年

全球濫用藥物 (DOA) 檢測市場規模預計將從 2022 年的 52 億美元增至 2027 年的 81 億美元，預測期內的複合年成長率為 9.3%。

全球生物工程蛋白質藥物市場規模預計將從 2022 年的 3,541 億美元增至 2027 年的 5,213 億美元，預測期內的複合年成長率為 8.0%。

全球疼痛管理藥物和設備市場規模預計將從 2023 年的 年終的 1,099 億美元，預測期內的複合年成長率為 5.4%。

醫藥市場是世界上最大的產業之一，並且不斷成長。在製藥業，研究和開發始終在進行中，包括推出新藥和改善現有藥物的性能。然而，新藥從研發到上市大概需要12到13年的時間，而現有藥物的價格卻在不斷上漲，這種情況導致醫藥市場持續成長。

研究和開發受技術和科學進步的推動，特別是細胞和基因治療，並在醫藥市場的成長中發揮關鍵作用。市場受到嚴格的監管和報銷政策以及不斷上升的研發成本的影響。人工智慧在製藥業的多個領域得到應用並被認為至關重要，其中包括藥物發現、臨床試驗、藥物篩檢、個人化醫療、藥物安全檢測和行銷洞察。生成式 AI 工具可以透過自動執行繁瑣且耗時的任務來幫助加速藥物發現。

本研究評論包括 BCC Research 於 2023 年發布的有關抗肥胖藥物、濫用藥物檢測、生物工程蛋白質藥物以及疼痛管理藥物和設備的報告的亮點和摘錄，並提供了每個市場的全面概述、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展趨勢、市場規模趨勢和預測，以及各個細分市場和地區的詳細分析。

目錄

第 1 章 簡介

2. 全球抗肥胖藥物市場（PHM281A）

• 抗肥胖藥物
• 市場概況
• 抗肥胖藥物市場概況
• 成人肥胖和超重的定義
• 肥胖問題加劇
• 肥胖對全球經濟的影響
• 提高對肥胖的認知
• 全球抗肥胖藥物市場（按類型）
• 處方藥
• 非處方藥
• 全球抗肥胖藥物市場（按分銷管道）
• 醫院藥房
• 零售藥局
• 網路藥局
• 全球抗肥胖藥物市場（按地區）
• 北美洲
• 歐洲
• 亞太地區
• 其他地區
• ESG 抗肥胖藥物開發
• ESG 在減重藥物產業的重要性
• 抗肥胖藥物產業的 ESG 支柱
• ESG評級與指標：解讀資料
• 減肥藥產業的 ESG 實踐
• BCC的結語

3. 藥物濫用檢測：技術與全球市場（PHM013J）

• 藥物濫用檢測的市場和技術背景
• 概述
• 檢測技術
• 單參數和多參數測試
• DOA篩檢
• 波特五力分析
• 藥物濫用檢測的市場動態
• 市場促進因素
• 市場限制
• 市場機會
• 藥物濫用檢測的監管情景
• 北美洲
• 南美洲
• 中美洲和加勒比海地區
• 歐洲
• 亞太地區
• 全球藥物濫用檢測市場（按藥物類型）
• 酒精
• 安非他命和甲基安非他命
• 大麻
• 古柯鹼
• 鴉片類藥物
• 其他
• 全球藥物濫用檢測市場（按最終用戶分類）
• 藥物檢測實驗室
• 醫院
• 職場
• 其他
• 全球藥物濫用檢測市場（按地區）
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

4. 全球生物工程蛋白質藥物市場（BIO009H）

• 生物工程蛋白質藥物
• 市場概況
• 生物工程蛋白質藥物的市場及技術背景
• 蛋白質治療概述
• 生物工程蛋白質藥物
• 生物工程蛋白質藥物製造技術
• 從天然來源（人類/動物）分餾/萃取
• 微生物發酵和生物反應器
• 基因改造
• 哺乳動物細胞培養
• 生物工程蛋白質藥物的市場動態
• 市場推進因素
• 市場挑戰
• 生物工程蛋白質藥物市場按藥物類型細分
• 概述
• 單株抗體（mAb）
• 肽激素
• 疫苗
• 融合蛋白
• 血液因素
• 胜肽類抗生素
• 細胞激素
• 治療性酵素
• 生物工程蛋白質藥物市場依疾病分類
• 概述
• 生物工程蛋白質藥物市場按地區細分
• 北美市場按藥物類型分類的收益
• 歐洲市場按藥物類型分類的收益
• 新興市場收益（按藥物類型）
• 生物工程蛋白質藥物市場的監管方面和新核准
• 新核准
• 市場新趨勢/未來技術
• 雙特異性和多特異性抗體
• 生物製藥產業的主要趨勢

5. 全球疼痛管理藥物和設備市場（HLC026G）

• 疼痛管理藥物和設備
• 市場概況
• 疼痛管理藥物和設備市場亮點
• 疼痛管理藥物和設備市場概況
• 疼痛史及疼痛治療
• 疼痛感知
• 疼痛類型
• 疼痛評估
• 如何診斷疼痛
• 治療疼痛的方法
• 疼痛管理藥物和設備市場動態
• 市場促進因素
• 市場限制
• 市場挑戰
• 疼痛管理藥物和設備市場按產品細分
• 藥品
• 疼痛管理設備
• 疼痛管理藥物和設備市場按應用細分
• 肌肉骨骼疼痛
• 術後疼痛
• 神經病變疼痛
• 癌症痛
• 偏頭痛
• 其他
• 疼痛管理藥物和設備市場按地區細分
• 北美洲
• 歐洲
• 亞太地區
• 其他地區
• ESG 發展
• ESG：簡介
• 疼痛管理藥物和設備產業的永續性：ESG 視角
• 案例研究
• BCC的結語
• 疼痛管理藥物和設備的新技術
• 概述
• 鴉片類藥物的技術進步
• 非麻醉藥品的技術進步
• 神經調節設備的技術進步
• 輸液幫浦的技術進步
• 疼痛管理趨勢

第6章 附錄

The global market for drugs of abuse (DOA) testing is estimated to increase from $5.2 billion in 2022 to reach $8.1 billion by 2027, at a compound annual growth rate (CAGR) of 9.3% from 2022 through 2027.

The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.

The global market for pain management drugs and devices is expected to increase from $84.6 billion in 2023 to $109.9 billion by the end of 2028, with a compound annual growth rate (CAGR) of 5.4% during the forecast period of 2023-2028.

Research Review Scope

The pharmaceutical market is one of the biggest industries in the world, and it is continuously growing. Continuous and ongoing research and development are happening in the pharmaceutical market, with the entry of new drugs and the performance of the current drugs. However, a drug's entry into the market takes around 12-13 years, but the market for existing drugs keeps soaring, which is why the pharmaceutical market keeps growing.

Research and development play a vital role in the growth of the pharmaceutical market, driven by technological and scientific advancements, especially in cell and gene therapies. The market is affected by stringent regulatory and reimbursement policies and escalating research and development costs. Artificial intelligence can be considered crucial with its usage in multiple fields of pharmaceuticals, such as drug discovery, clinical trials, drug screening, personalized medicine, supply chain management, regulatory compliance, pharmacovigilance, and marketing insights. Generative AI tools help accelerate drug discovery by automating tedious and time-consuming tasks.

Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. This 2023 Pharmaceuticals Research Review provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions. This Research Review includes highlights and excerpts from the following reports published by BCC Research in 2023:

PHM281A Anti Obesity Drugs Market

• PHM013J Drugs of Abuse Testing: Technologies and Global Markets
• BIO009H Global Markets for Bioengineered Protein Drugs
• HLC026G The Global Market for Pain Management Drugs and Devices

After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.

Table of Contents

Chapter 1 Foreword

• Research Review Scope

Chapter 2 Global Market for Anti-obesity Drugs (PHM281A)

• Anti-obesity Drugs
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• Market Outlook
• Market Summary
• Market Overview of Anti-obesity Drugs
• Definitions of Adult Obesity and Overweight
• Rising Prevalence of Obesity
• Impact of Obesity on Global Economy
• Increasing Awareness Regarding Obesity
• Global Market for Anti-obesity Drugs, by Type
• Prescription Drugs
• Over-the-Counter Anti-obesity Drugs
• Global Market for Anti-obesity Drugs, by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Market for Anti-obesity Drugs, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
• ESG Developments of Anti-obesity Drugs
• Importance of ESG in Anti-obesity Drugs Industry
• ESG Pillars in the Anti-obesity Drug Industry
• ESG Ratings and Metrics: Understanding the Data
• ESG Practices in the Anti-obesity Drug Industry
• Concluding Remarks from BCC

Chapter 3 Drugs of Abuse Testing: Technologies and Global Markets (PHM013J)

• Drugs of Abuse Testing
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Summary and Highlights
• Market and Technology Background of Drugs of Abuse Testing
• Overview
• Testing Technologies
• Single Tests vs. Multiparameter Tests
• DOA Screening
• Porter's Five Forces Analysis of Drugs of Abuse Testing
• Market Dynamics of Drugs of Abuse Testing
• Market Drivers
• Market Restraints
• Market Opportunities
• Regulatory Scenario of Drugs of Abuse Testing
• North America
• South America
• Central America and the Caribbean
• Europe
• Asia-Pacific
• Global Drugs of Abuse Testing Market, by Drug Type
• Alcohol
• Amphetamine and Methamphetamine
• Cannabis/Marijuana
• Cocaine
• Opioids
• Others
• Global Drugs of Abuse Testing Market, by End User
• Drug Testing Laboratories
• Hospitals
• Workplaces
• Others
• Market Breakdown of Drugs of Abuse Testing, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 4 Global Markets for Bioengineered Protein Drugs (BIO009H)

• Bioengineered Protein Drugs
• Study Goals and Objectives
• Scope of This Report
• Market Summary
• Market and Technology Background of Bioengineered Protein Drugs
• Protein Drugs Overview
• Bioengineered Protein Drugs
• Manufacturing Technologies of Bioengineered Protein Drugs
• Fractionation/Extraction from Natural Sources (Human/Animal)
• Microbial Fermentation and Bioreactors
• Transgenics
• Mammalian Cell Culture
• Market Dynamics of Bioengineered Protein Drugs
• Market Driver
• Market Challenges
• Market Breakdown of Bioengineered Protein Drugs by Drug Type
• Overview
• Monoclonal Antibodies (mAbs)
• Peptide Hormones
• Vaccines
• Fusion Proteins
• Blood Factors
• Peptide Antibiotics
• Cytokines
• Therapeutic Enzymes
• Market Breakdown of Bioengineered Protein Drugs, by Disease
• Overview
• Market Breakdown of Bioengineered Protein Drugs, by Region
• North America Market Revenue, by Drug Type
• Europe Market Revenue, by Drug Type
• Emerging Markets Revenue, by Drug Type
• Regulatory Aspects and New Approvals of Bioengineered Protein Drugs Market
• New Approvals
• Emerging Trends/Upcoming Technologies in the Market
• Bi- and Multi-Specific Antibodies
• Key Trends in Biopharmaceutical Industry

Chapter 5 Global Market for Pain Management Drugs and Devices (HLC026G)

• Pain Management Drugs and Device
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• Market Outlook
• Market Summary
• Highlights of the Market for Pain Management Drugs and Devices
• Market Overview of Pain Management Drugs and Device
• History of Pain and Pain Treatment
• The Perception of Pain
• Types of Pain
• Assessment of Pain
• How Pain is Diagnosed
• How Pain is Treated
• Market Dynamics of Pain Management Drugs and Device
• Market Drivers
• Market Restraints
• Market Challenges
• Market Breakdown of Pain Management Drugs and Device, by Product
• Pharmaceuticals
• Pain Management Devices
• Market Breakdown of Pain Management Drugs and Device, by Application
• Musculoskeletal Pain
• Post-operative Pain
• Neuropathic Pain
• Cancer Pain
• Migraine/Headache
• Other Applications
• Market Breakdown of Pain Management Drugs and Device, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
• ESG Development of Pain Management Drugs and Device
• Introduction to ESG
• Sustainability in the Pain Management Drugs and Devices Industry: An ESG Perspective
• Case Study
• Concluding Remarks from BCC
• Emerging Technologies of Pain Management Drugs and Device
• Overview
• Technology Advancements in Opioid Drugs
• Technology Advancements in Non-narcotic Drugs
• Technology Advancements in Neuromodulation Devices
• Technology Advancements in Infusion Pumps
• Trends in Pain Management

Chapter 6 Appendix

• Methodology
• Analyst's Credentials

List of Tables

• Table 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
• Table 2 : Definitions of Adult Obesity and Overweight
• Table 3 : Number of People, Aged Over 5 Years, and Percentage of the Population With Overweight or Obesity, 2020-2035
• Table 4 : Global Obesity Trends for Children and Adolescents, Aged 5 to 19 Years, by Gender, 2020-2035
• Table 5 : Global Obesity Trends for Adults, Aged 20 Years and Above, by Gender, 2020-2035
• Table 6 : Global Economic Impact of High BMI (BMI >=25kg/m2), 2020-2035
• Table 7 : Global Market for Anti-obesity Drugs, by Drug Type, Through 2028
• Table 8 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
• Table 9 : Global Market for Anti-obesity Drugs, by Region, Through 2028
• Table 10 : ESG Ratings and Metrics of Anti-obesity Drugs
• Table 11 : Environmental Performance of Anti-obesity Drugs
• Table 12 : Social Performance of Anti-obesity Drugs
• Table 13 : Governance Performance of Anti-obesity Drugs
• Table 14 : ESG Rankings for Major Anti-obesity Drug Companies, 2023*
• Table 15 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
• Table 16 : Cutoff Concentrations for Initial and Confirmatory Drug Tests in Urine
• Table 17 : Deaths from Tobacco, Alcohol and Drugs, Across Countries, 2019
• Table 18 : Commonly Abused Drugs
• Table 19 : Prevalence of Drug Use in General, Population Across Region, 2020
• Table 20 : Global Drug Seizure, by Drug Type, 2020
• Table 21 : U.S. Drug Testing Legislation, by State, 2017
• Table 22 : European Drug Testing Legislation, by Country
• Table 23 : Global Market for Drugs of Abuse Testing, by Region, Through 2027
• Table 24 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
• Table 25 : Characteristics of Large Molecule/Protein Drugs
• Table 26 : Bioengineered Protein Drugs vs. Chemically Synthesized Drugs
• Table 27 : Selected Protein Drugs Made, by Fractionation
• Table 28 : Selected Therapeutic Drugs Produced, by Microbial Fermentation
• Table 29 : Selected Protein Drugs Produced, by Transgenic Animals, Plants, and Microorganisms
• Table 30 : Selected Protein Drugs Made, by Cell Culture
• Table 31 : Number and Distribution of Persons Aged 60+, by Region, 2019 and 2050
• Table 32 : Global Pipeline Molecules, by Type, Through 2021
• Table 33 : Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
• Table 34 : Percentage of Major Proteins Present in Different Fractions After Cohn's Fractionation Method
• Table 35 : Global Market for Bioengineered Protein Drugs, by Disease, Through 2027
• Table 36 : Global Market for Bioengineered Protein Drugs, by Region, Through 2027
• Table 37 : Newly Approved Monoclonal Antibodies (mAbs), January 2021-December 2022
• Table 38 : Newly Approved Peptide Hormones and Drugs, January 2021-December 2022
• Table 39 : Newly Approved Vaccines, January 2021-December 2022
• Table 40 : Vaccine Candidates in Clinical Phase, January 2021-December 2022
• Table 41 : Newly Approved Blood Factors, January 2021-December 2022
• Table 42 : Newly Approved Peptide Antibiotics, January 2021-December 2022
• Table 43 : Newly Approved Therapeutic Enzymes, January 2021-December 2022
• Table 44 : Newly Approved Cytokines, January 2021-December 2022
• Table 45 : Newly Approved Fusion Protein, January 2021-December 2022
• Table 46 : Selected Bi-Specific Antibodies in Phase 3 Clinical Trials, 2023
• Table 47 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
• Table 48 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Table 49 : Objective Signs of Pain
• Table 50 : Prevalence of Chronic Pain in Older Adults, by Site
• Table 51 : Opioid Lawsuit Settlements
• Table 52 : Global Market for Pain Management Drugs and Devices, by Product, Through 2028
• Table 53 : FDA Pain Management Drug Approvals, 2020-2023
• Table 54 : Pain Management Major Drugs, by Company
• Table 55 : Emerging Pain Therapeutics
• Table 56 : Global Market for Pain Management Pharmaceuticals, by Product, Through 2028
• Table 57 : Global Market for Pain Management Devices, by Type, Through 2028
• Table 58 : Global Market for Pain Management Drugs and Devices, by Application, Through 2028
• Table 59 : Cumulative Volumes of Hip and Knee Procedures, 2012-2021
• Table 60 : Neuropathic Pain Medication
• Table 61 : Cancer Pain Medication
• Table 62 : Global Market for Pain Management Drugs and Devices, by Region, Through 2028
• Table 63 : ESG Ranking of Major Pharma Players for Pain Therapeutics, 2022
• Table 64 : ESG Rankings for Major Pain Management Drug and Device Companies, 2023*
• Table 65 : ESG: Environmental Overview
• Table 66 : ESG: Social Overview
• Table 67 : ESG: Governance Overview

List of Figures

• Figure 1 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
• Figure 2 : Global Market for Anti-obesity Drugs, by Drug Type, 2021-2028
• Figure 3 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
• Figure 4 : Global Market Shares of Anti-obesity Drugs, by Region, 2021-2028
• Figure 5 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
• Figure 6 : Annual Self-reported Alcohol-impaired Driving Episodes Among U.S. Adults, 2010-2020
• Figure 7 : Legal Adult-Use Cannabis Sales Worldwide, 2020-2025*
• Figure 8 : Global Market Shares of Drugs of Abuse Testing, by Region, 2021
• Figure 9 : Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
• Figure 10 : Global Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
• Figure 11 : Global Market Shares of Bioengineered Protein Drugs, by Disease, 2021
• Figure 12 : Snapshot of Global Market for Bioengineered Protein Drugs, by Region
• Figure 13 : Global Market Shares of Bioengineered Protein Drugs, by Region, 2021
• Figure 14 : NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
• Figure 15 : Share of NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
• Figure 16 : Global Market for Pain Management Drugs and Devices, by Product, 2020-2028
• Figure 17 : Global Market for Pain Management Drugs and Devices, by Region, 2020-2028
• Figure 18 : Pain Management Techniques
• Figure 19 : Pain Management Drugs and Devices: Market Dynamics
• Figure 20 : Common Chronic Pain: Reasons
• Figure 21 : Cancer Incidence, by Region, 2020 vs. 2040
• Figure 22 : Percentage of Global Population Above 65 Years, 2018-2022
• Figure 23 : Global Market Shares of Pain Management Drugs and Devices , by Product, 2022
• Figure 24 : Global Market Shares of Pain Management Pharmaceuticals, by Product, 2022
• Figure 25 : Global Market Shares of Pain Management Devices, by Type, 2022
• Figure 26 : Global Market Shares of Pain Management Drugs and Devices, by Application, 2022
• Figure 27 : Classification of Neuropathic Pain
• Figure 28 : Causes of Cancer Pain
• Figure 29 : Burn Pain Management Approach
• Figure 30 : Global Market Shares of Pain Management Drugs and Devices, by Region, 2022
• Figure 31 : ESG Pillars
• Figure 32 : Advantages of ESG for Companies
• Figure 33 : ESG-Adoption Level across Industries
• Figure 34 : Hospitals: Sustainability Priorities
• Figure 35 : Novartis: ESG Rating
• Figure 36 : Novartis: Major ESG Activities, 2022